Back

Human induced pluripotent stem cell-derived cardiomyocytes (and other cells)

19 June 2026 (09:30 - 09:45)
Organised by: Logo
Congress Presentation Part of: Which is the best model to study cancer treatment-related cardiovascular toxicity? Cardio-Oncology CCO Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Paul Burridge

Northwestern University Feinberg School of Medicine, Chicago (United States of America)

3 More presentations in this session

Presentation thumbnail
Large animals
Mr C. Galan (Madrid, ES)
Slides
Presentation thumbnail
Cancer and cachexia : the pivotal role of IL-6 signaling
Associate Professor A. Kiss (Vienna, AT)
Slides
Presentation thumbnail
Which is the best model to study cancer treatment-related cardiovascular toxicity? - discussion

Access the full session

Session thumbnail
Which is the best model to study cancer treatment-related cardiovascular toxicity?
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 09:30 CET
You may be interested in
thumbnail
Webinar
Induced-pluripotent stem cells (iPSC) technology for cardiac repair
17 March 2022
thumbnail
Congress Presentation
Purification of human iPSC-derived cardiomyocytes by HDAC inhibition through inducing apoptosis and cell arrest in non-cardiomyocytes
28 August 2020
thumbnail
Congress Presentation
Ca2+ handling in induced-pluripotent cardiomyocytes from female CPVT patient, and comparison to male.
23 April 2021
thumbnail
Congress Presentation
Melt electrowritten 3D human cardiac engineered tissues reproduce the enhanced sensitivity of fibrotic patients to doxorubicin
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources